// App-Quantinova.ai

1473 : Mechanism of action of bempegaldesleukin (BEMPEG) plus nivolumab (NIVO) in patients with unresectable or metastatic melanoma from the phase 3 randomized open-label PIVOT IO-001 clinical trial

Researchers

Presenter

  • Celeste Lebbe

Principal Investigators

  • Shruthi Ravimohan

  • Antara Datta

  • Aparna Chhibber

  • Eva Munoz Couselo

  • Caio Pereira

  • Shahneen Sandhu

  • Ming Zhou

  • Brendan Curti

  • Nikhil Khushalani

  • Matthew Taylor

  • Alfonsus Van Den Eertwegh

  • Ute Hoch

  • Georgina Long AO

  • Yull Arriaga

  • Adi Diab

  • Helen Gogas

Medical Centers

  • Providence Cancer Institute, Portland, OR, USA

  • 1.MD Anderson Cancer Center, Houston, TX

  • Melanoma Institute Australia, The University of Sydney, Royal North Shore and Mater Hospitals, Sydney, Australia

  • Greater Paris University Hospitals, Paris, France

  • National and Kapodistrian University of Athens, Athens, Greece

  • Bristol-Myers Sqiubb, Princeton, NJ

  • Vall d'Hebron Hospital, Vall d'Hebron Institute of Oncology, Barcelona, Spain

  • VU Amsterdam, Amsterdam, Netherlands

  • Moffitt Cancer Center, Tampa, FL

  • Fundacao Pio Xii Hosp Cancer De Barretos, Barretos, Brazil

  • Nektar Therapeutics, San Francisco, CA

  • Peter MacCallum Cancer Centre, East Melbourne, Australia

Locations

  • United States

  • Greece

  • Brazil

  • Australia

  • Spain

  • France

  • Netherlands

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Melanoma

Biomarkers

  • Cluster of Differentiation 25

  • Cluster of Differentiation 4

  • Forkhead Box P3

  • Programmed death-ligand 1

  • Proliferation marker protein Ki-67

  • Cluster of differentiation 8A

  • Interferon-gamma

  • tumor-infiltrating lymphocytes

  • Regulatory T cells

Drug/Treatment

  • Interferon Gamma

  • Nivolumab

Outcome

  • N/A

Study Design

  • Randomized

  • Open Label

Phase

  • III

Study Id's

  • NCT03635983

Sponsors

  • N/A

Result

  • Final

Copyright © 2026. QuantiNova All rights reserved